Property | TMEM213 | TMEM207 | TMEM61 | TMEM45B | TMEM30B | RTP3 | TMEM72 | TMEM116 | SLC35G2 | TMEM45A | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Full name | transmembrane protein 213 precursor | transmembrane protein 207 precursor | transmembrane protein 61 | transmembrane protein 45B | transmembrane protein 30B | receptor-transporting protein 3 | transmembrane protein 72 | transmembrane protein 116 isoform 1 | solute carrier family 35 member G2 | transmembrane protein 45A | ||||||||||||||||||||||
Alternative names | – | UNQ846 | – | – | CDC50B | LTM1; TMEM7 | KSP37; C10orf127; bA285G1.3 | – | TMEM22 | DERP7 | ||||||||||||||||||||||
NP (NCBI) | 001078898.1 | 997199.1 | 872338.1 | 620143.1 | 001017970.1 | 113628.1 | 001116848.1 | 001180460.1 | 079522.2 | 060474.1 | ||||||||||||||||||||||
GI | 146229352 | 46409276 | 32698902 | 20270331 | 63003930 | 13899263 | 183227675 | 302058299 | 148224156 | 8922243 | ||||||||||||||||||||||
Protein isoforms | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | ||||||||||||||||||||||
Transcript variants | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | ||||||||||||||||||||||
Human length (aa) | 107 | 146 | 210 | 275 | 351 | 232 | 275 | 337 | 412 | 275 | ||||||||||||||||||||||
Pfam | TMEM213 family in eukaryotes; 154 aa; unknown function | n/a | TMEM61 family in eukaryotes; 150–211 aa; unknown function | DUF716 family in metazoa (unknown function) and plants (response to viral attack) | CDC50/ LEM3 (ligand-effect modulator 3) family in glucocorticoid receptor pathway | zf-3CxxC family with zinc-binding domain | n/a | n/a | EamA drug/metabolite transporter-like family with two copies of EamA domain | DUF716 family in metazoa (unknown function) and plants (response to viral attack) | ||||||||||||||||||||||
Tertiary structure prediction1 | n/a | Similar to TM protein stannin (PDB Id: 1zza) | n/a | n/a | n/a | Similar to Zn-binding proteins (PDB Id: 2cup; 2dkt; 2e2z; 3hcs) | n/a | Similar to human adrenoreceptor (PDB Id: 2rh1; 2r4r) and human adenoreceptor (PDB Id: 3eml) | Similar to TM domain of the multidrug-resistance antiporter from E. coli EmrE (PDB Id: 3b5d) | n/a | ||||||||||||||||||||||
TM domains | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 7 | 7 | 7 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 4 | 1 | 6 | 6 | 3 | 10 | 10 | 8 | 7 | 7 | 5 | ||
1 | 2 | 3 | ||||||||||||||||||||||||||||||
Predicted topology3 | Type 1a with cyt tail (92 to 107) | Type 1a with cyt tail (71 to 146) | Type 3a | Type 3b | Type 3a | Type Nt with cyt tail (1 to 211) | Type 2 with cyt tail (1 to 94) | Type 3a | Type 3a | Type 3a | ||||||||||||||||||||||
Cleavable N-terminal signal peptide3 | Yes (1 to 27) | Yes (1 to 29) | No | No | No | No | No | Yes (1 to 50) | No | No | ||||||||||||||||||||||
Cytoplasmic/ Nuclear discrimination3 | Nuc (55.5) | Cyt (94.1) | Nuc (70.6) | Cyt (94.1) | Cyt (89) | Cyt (89) | Cyt (94.1) | Cyt (94.1) | Cyt (94.1) | Cyt (94.1) | ||||||||||||||||||||||
Subcellular localization3 | ER (44.4Â %) | ER (44.4Â %) | Mit (39.1Â %) Nuc (34.8Â %) | ER (66.7Â %) | ER (39.1Â %) Mit (39.1Â %) | Cyt (30.4Â %) | Mit (30.4Â %) | ER (43.5Â %) | ER4 (55.6Â %) | ER (77.8Â %) |